Danazol treatment for advanced breast cancer

R. Charles Coombes, David Pérez, J.-C. Gazet, H.T. Ford, TrevorJ. Powles
In: Cancer Chemotherapy and Pharmacology · 1983 · vol. 10(3) , pp. 194–5 · doi:10.1007/bf00255761 · PMID:6345017 · W1974235591
article OA: closed CC0 ⤵ 5 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

Danazol treatment in advanced breast cancer patients resulted in a 14.9% response rate and 9% disease stabilization, with moderate tolerability but inferior efficacy compared to tamoxifen or aminoglutethimide.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-11 · read from full text ⓘ

This study treated 69 pre- and post-menopausal patients with advanced breast cancer with danazol, administered for durations ranging from 3 days to 30 months, and assessed clinical response, disease stabilization, progression, and tolerability. Ten patients (14.9%) responded for 3–19 months (mean 10 months), six (9%) had disease stabilization, 45 showed progression after treatment, and eight were unassessable. Side effects occurred in 17 (25%) and required therapy reduction in eight cases. The study concludes danazol was moderately well tolerated and effective but had an inferior response rate compared with other endocrine agents such as tamoxifen or aminoglutethimide. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Pre-menopausal (14) and post-menopausal (55) patients with advanced breast cancer were treated with danazol (Danol) for periods ranging between 3 days and 30 months. Of these, 10 patients (14.9%) responded to treatment for 3-19 months (mean 10 months); a further six patients (9%) showed stabilisation of disease; 45 patients showed clear progression of disease following treatment; and eight patients were unassessable. Side-effects occurred in 17 of 69 patients (25%) and necessitated a reduction in therapy in eight cases. It is concluded that danazol is moderately well tolerated and is an effective agent in patients with advanced breast cancer, but the response rate is inferior to that of other agents in current use, such as tamoxifen or aminoglutethimide.
Full text 2,441 characters · extracted from oa-doi-fallback · click to expand
Summary Pre-menopausal (14) and post-menopausal (55) patients with advanced breast cancer were treated with danazol (Danol) for periods ranging between 3 days and 30 months. Of these, 10 patients (14.9%) responded to treatment for 3–19 months (mean 10 months); a further six patients (9%) showed stabilisation of disease; 45 patients showed clear progression of disease following treatment; and eight patients were unassessable. Side-effects occurred in 17 of 69 patients (25%) and necessitated a reduction in therapy in eight cases. It is concluded that danazol is moderately well tolerated and is an effective agent in patients with advanced breast cancer, but the response rate is inferior to that of other agents in current use, such as tamoxifen or aminoglutethimide. Similar content being viewed by others References Coombes RC, Dearnaley D, Humphreys J, Gazet J-C, Ford HT, Nash AG, Mashiter K, Powles TJ (1980a) Danazol treatment of advanced breast cancer. Cancer Treat Rep 64:1073 Coombes RC, Powles TJ, Gazet J-C, Nash AG Ford HT, McKinna A, Neville AM (1980b) Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet I:196 Coombes RC, Powles TJ, Rees LH Ratcliffe WA, Nash AG, Henk M Ford HT, Gazet J-C, Neville AM (1982) Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer. Br J Cancer 46:30 Greeblatt RB, Dmowski WP, Makesh VB (1971) Clinical studies with an antigonadotropin—danazol. Fertil Steril 22:9 Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39:1289 McGuire WL, Carbone PP, Sears ME (1975) Estrogen receptors in human breast cancer. Raven Press, New York pp 1–7 Potts GO (1977) Pharmacology of danazol. J Int Med Res [Suppl 3] 5:1 Powles TJ, Gordon C, Coombes RC (1982) Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone. Cancer Res 42: 3458S Author information Authors and Affiliations Rights and permissions About this article Cite this article Charles Coombes, R., Perez, D., Gazet, JC. et al. Danazol treatment for advanced breast cancer. Cancer Chemother. Pharmacol. 10, 194–195 (1983). https://doi.org/10.1007/BF00255761 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/BF00255761

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (5)

Source provenance

openalex
last seen: 2026-05-10T11:47:42.047208+00:00
License: CC0 · commercial use OK